Annals of Allergy Asthma & Immunology最新文献

{"title":"Vanishing Allergen: Addressing the Crisis of American Elm Pollen Extracts in Allergy Treatment.","authors":"Maureen M Petersen, Joseph P Forester, Richard Lankow, Rosemary Moak, J Allen Meadows","doi":"10.1016/j.anai.2025.04.001","DOIUrl":"https://doi.org/10.1016/j.anai.2025.04.001","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare-Seeking Behaviors for Acute Asthma: A US Cross-sectional Survey.","authors":"Donna D Gardner, Raj Gokani, Juliana Hey-Hadavi, Dennis Williams, Mario Castro, Elliot Israel, Andres Quintero","doi":"10.1016/j.anai.2025.03.025","DOIUrl":"https://doi.org/10.1016/j.anai.2025.03.025","url":null,"abstract":"<p><strong>Background: </strong>Understanding patient motivations for acute care-seeking behavior for asthma attacks could guide interventions to improve outcomes and mitigate healthcare resource use.</p><p><strong>Objective: </strong>To characterize healthcare seeking behaviors and motivations of patients in the US who obtain care for an asthma attack in urgent care (UC), emergency department (ED), or hospital settings.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted online between July-August 2023 among adults in a market research panel treated for asthma in the past 12 months and who had experienced an asthma attack that required care in an UC, ED, or hospital or an oral corticosteroid prescription.</p><p><strong>Results: </strong>Of the 504 survey participants (female=72%; White=79%; Hispanic=12%), 68% self-reported asthma of moderate severity and 72% had uncontrolled asthma. Oral corticosteroids were prescribed an average of 4.2 times over the past year. During their last asthma attack, 37% of participants took medicines at home, 20% went to UC, 15% went to the ED, and 5% were hospitalized. Participants who were younger, Asian, Hispanic, or with severe asthma were the most likely to go to the ED. Using a rescue inhaler was the most common action taken when first experiencing symptoms (72%). When participants considered seeking acute care, the severity of asthma symptoms was the most common factor considered (76%), followed by fast access to help (29%) and medication access (28%).</p><p><strong>Conclusion: </strong>The majority of patients seeking acute asthma care reported moderately severe, uncontrolled disease. Seeking acute care appears to be motivated by symptom severity and the need for fast access to care after trying rescue medications. It would be of interest in a future study to also evaluate the acute care seeking needs of patients who are at lower-risk of seeking acute care.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Mast Cell Activation Disorders and Hereditary Alpha Tryptasemia Amongst POTS and EDS Patients: A Systematic Review.","authors":"Matthew Farley, Ricardo J Estrada-Mendizabal, Emily A Gansert, Dayne Voelker, Lisa A Marks, Alexei Gonzalez-Estrada","doi":"10.1016/j.anai.2025.03.022","DOIUrl":"https://doi.org/10.1016/j.anai.2025.03.022","url":null,"abstract":"<p><strong>Background: </strong>Postural Orthostatic Tachycardia Syndrome (POTS) and Ehlers-Danlos Syndrome (EDS) are often reported to occur concurrently with Mast Cell Activation Disorders (MCADs) and Hereditary Alpha Tryptasemia (HAT). However, it remains unclear whether evidence supporting this relationship exists.</p><p><strong>Objective: </strong>To determine the prevalence of MCADs and HAT in patients diagnosed with EDS and or POTS.</p><p><strong>Methods: </strong>We conducted a systematic search of MEDLINE (OVID), EMBASE (OVID), Scopus, and Web of Science with the assistance of an experienced medical librarian. We focused on patients with any MCAD or HAT in conjunction with a diagnosis of POTS and/or EDS.</p><p><strong>Results: </strong>A total of 200 records were screened, 107 were excluded based on the title or abstract, 92 full texts were reviewed, and one record was not retrieved. No studies were identified that met our primary criterion of including patients diagnosed with any MCAD or HAT alongside POTS and/or EDS based on our pre-specified diagnostic criteria.</p><p><strong>Conclusion: </strong>Our review did not find evidence to confirm a relationship between MCADs, HAT, POTS, and EDS. However, it must be mentioned that one study showed an association between MCAS, POTS, and EDS and came close to meeting the full diagnostic criteria for MCAS, unlike other studies. This indicates that further research using strict and validated diagnostic criteria is needed to clarify whether a true association between conditions exists.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From the pages of AllergyWatch","authors":"Stanley M. Fineman MD ,&nbsp;Shyam R. Joshi MD ,&nbsp;Gerald B. Lee MD ,&nbsp;Timothy Chow MD","doi":"10.1016/j.anai.2025.01.016","DOIUrl":"10.1016/j.anai.2025.01.016","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 495-496"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' response","authors":"Rory Chan PhD, FRCPE ,&nbsp;Carlo Lombardi MD ,&nbsp;Pasquale Comberiati MD ,&nbsp;Alvise Berti MD ,&nbsp;Francesco Menzella MD ,&nbsp;Ronald J. Dandurand MD ,&nbsp;Zuzana Diamant MD, PhD ,&nbsp;Marcello Cottini MD","doi":"10.1016/j.anai.2025.01.008","DOIUrl":"10.1016/j.anai.2025.01.008","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 491-492"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highly accurate, noninvasive early identification of infants with a filaggrin loss-of-function mutation by in vivo Raman spectroscopy, followed from birth to 12 months","authors":"Gerwin J. Puppels PhD ,&nbsp;Jonathan O'B. Hourihane MD ,&nbsp;Claudio Nico PhD ,&nbsp;Carol Ni Chaoimh PhD ,&nbsp;Colin Wong BSc ,&nbsp;John E. Common PhD ,&nbsp;Peter J. Caspers PhD ,&nbsp;Alan D. Irvine MD, DSc","doi":"10.1016/j.anai.2025.01.010","DOIUrl":"10.1016/j.anai.2025.01.010","url":null,"abstract":"<div><h3>Background</h3><div>Loss-of-function <em>FLG</em> mutation (<em>FLGmut</em>) carriers are at an increased risk of developing atopic dermatitis (AD), characterized by earlier onset and more severe disease. AD is driven by a complex interplay between skin barrier function, T_H2 and T_H2-dominant immune dysregulation, and dysbiosis. Results from the Short-Term Topical Application for Prevention of Atopic Dermatitis study suggest 2 early initiating AD pathogenetic pathways: an <em>FLGmut</em>-related skin barrier deficiency pathway and an immune function-related inflammatory pathway. The Short-Term Topical Application for Prevention of Atopic Dermatitis study suggested that early preventative intervention with specialized emollients for barrier function augmentation may benefit newborns with <em>FLGmut</em>. This requires early identification of <em>FLGmut</em> carriers, for which noninvasive Raman spectroscopic determination of natural moisturizing factor (NMF) levels in the stratum corneum of the thenar eminence provides a surrogate marker.</div></div><div><h3>Objective</h3><div>To identify strategies for early identification of infants with <em>FLGmut</em>.</div></div><div><h3>Methods</h3><div><em>FLG</em> sequencing was performed on 253 infants, and NMF concentrations were measured in the stratum corneum of the palmar eminence (pSC-NMF) using noninvasive Raman spectroscopy at 6 time points after birth. Furthermore, the pSC-NMF concentrations were obtained from both parents of 150 infants.</div></div><div><h3>Results</h3><div>Babies are born with little to no NMF. In the first days after birth, NMF levels rapidly increase and 65% of newborns with <em>FLG</em> wild type already reach pSC-NMF concentrations, which excludes them as <em>FLGmut</em> carriers with high specificity. At 2 weeks of age, <em>FLGmut</em> carriers could be distinguished from newborns with <em>FLG</em> wild type with high sensitivity (97%) and specificity (97%). In addition, parent pSC-NMF concentrations offer the possibility to exclude their newborn as <em>FLGmut</em> carriers with high specificity.</div></div><div><h3>Conclusion</h3><div>Noninvasive Raman spectroscopy enables the accurate early identification of infants with <em>FLGmut</em>.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 457-464"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Desensitization with telemedicine: A novel protocol using remote monitoring for oral immunotherapy for alpha-gal syndrome","authors":"Albert G. Wu MD ,&nbsp;Malina C. Patel MD ,&nbsp;Manish Ramesh MD, PhD","doi":"10.1016/j.anai.2025.01.001","DOIUrl":"10.1016/j.anai.2025.01.001","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 488-489"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The combination of allergen immunotherapy and biologics for inhalant allergies: Exploring the synergy","authors":"Bianca Olivieri MD ,&nbsp;Fatma Esra Günaydın MD ,&nbsp;Jonathan Corren MD ,&nbsp;Gianenrico Senna MD ,&nbsp;Stephen R. Durham MD","doi":"10.1016/j.anai.2024.06.016","DOIUrl":"10.1016/j.anai.2024.06.016","url":null,"abstract":"<div><div><span>The development of monoclonal antibodies that selectively target IgE and type 2 immunity has opened new possibilities in the treatment of allergies. Although they have been used mainly as single therapies found to have efficacy in the management of asthma and other T2-mediated diseases, there is a growing interest in using these monoclonal antibodies in combination with </span>allergen immunotherapy<span> (AIT). AIT has transformed the treatment of allergic diseases by aiming to modify the underlying immune response to allergens rather than just providing temporary symptom relief. Despite the proven efficacy and safety of AIT, unmet needs call for further research and innovation. Combination strategies involving biologics and AIT exhibit potential in improving short-term efficacy, reducing adverse events, and increasing immunologic tolerance. Anti-IgE emerges as the most promising therapeutic strategy, not only enhancing AIT's safety and tolerability but also providing additional evidence of efficacy compared with AIT alone. Anti–interleukin-4 receptor offers a reduction in adverse effects and an improved immunologic profile when combined with AIT; however, its impact on short-term efficacy seems limited. The combination of cat dander<span> subcutaneous immunotherapy with anti-thymic stromal lymphopoietin was synergistic with enhanced efficacy and altered immune responses that persisted for 1 year after discontinuation compared with AIT alone. Long-term studies are needed to evaluate the sustained benefits and safety profiles of combination strategies.</span></span></div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 385-395"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141428174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria","authors":"David M. Lang MD ,&nbsp;Javed Sheikh MD ,&nbsp;Shyam Joshi MD ,&nbsp;Jonathan A. Bernstein MD","doi":"10.1016/j.anai.2024.10.026","DOIUrl":"10.1016/j.anai.2024.10.026","url":null,"abstract":"<div><div>Chronic spontaneous urticaria (CSU) is an inflammatory disorder that manifests with hives, angioedema, or both and lasts more than or equal to 6 weeks. Although certain elements of CSU pathogenesis are well defined, others remain unclear. We discuss our current understanding of the underlying CSU endotypes, distinct clinical phenotypes, and predictive biomarkers. It is increasingly recognized that CSU comprises a spectrum of different underlying pathogenic mechanisms and distinct clinical presentations. Broadly, 2 endotypes that drive CSU pathogenesis have been identified, namely type I (autoallergic) and type IIb (autoimmune). However, a subpopulation shows evidence of both types, and some patients show evidence of neither. Multiple identified biomarkers have been associated with these endotypes or with disease features, such as CSU severity and duration. There is a lack of connectivity among the identified biomarkers, genetic risk loci, phenotypes, and corresponding endotypes, and each of these is frequently considered independently of the others. These identifiable features also have been associated with response, or lack thereof, to available therapies. Future investigations should optimize the endotyping of CSU using point-of-care, noninvasive, accessible biomarkers and assess the differences in response to therapy. With multiple treatments in late-stage development, establishing clearly defined CSU endotypes will facilitate future treatment decision-making and tailored treatment approaches and will inform optimal trial design.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 408-417.e3"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote oral immunotherapy updosing","authors":"Richard L. Wasserman MD, PhD","doi":"10.1016/j.anai.2025.01.011","DOIUrl":"10.1016/j.anai.2025.01.011","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"134 4","pages":"Pages 374-375"},"PeriodicalIF":5.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}